Literature DB >> 17998251

Predictors of arrhythmia recurrence in patients with lone atrial fibrillation.

Germán Arriagada1, Antonio Berruezo, Lluís Mont, David Tamborero, Irma Molina, Blanca Coll-Vinent, Bárbara Vidal, Marta Sitges, Paola Berne, Josep Brugada.   

Abstract

AIMS: The need for antiarrhythmic drugs (AAD) after a first episode of atrial fibrillation (AF) is determined by the probability of recurrence. The aim of this study was to asses the probability of relapse and the predictors of recurrence in patients with idiopathic AF. METHODS AND
RESULTS: A cohort of 98 consecutive patients younger than 65 years admitted at the emergency room because of an episode of symptomatic idiopathic (lone) AF was included in this study. On admission, a complete medical history was taken, and an echocardiogram and 24-h Holter monitoring were performed. Patients were seen at 3 and 6 months after the index episode. There were 35 (35.7%) patients with a new-onset AF episode and 63 (64.3%) with a recurrent AF episode. A majority of them were male (71%), with a mean age of 48+/-11 years. Patients with new-onset AF episodes did not receive AAD. At 6 month follow-up, 57% of all patients suffered at least one symptomatic AF relapse. Patients with AF relapses belong more often to the recurrent group vs. new-onset group of AF (65.1 vs. 34.9%, respectively, P = 0.03); they had larger LA diameter indexed for body surface area (BSA) (22.6+/-3.7 vs. 19.8+/-3.2 mm/m(2), P = 0.001), larger left ventricular end-systolic diameter (18.4+/-3.1 vs. 17.2+/-2.5 mm/m(2), P = 0.05) and a tendency towards a higher proportion of atrial tachycardia runs on Holter (66.7 vs. 50%, P = 0.09). Logistic regression analysis showed that the presence of previous episodes of AF (OR: 3.2; 95% CI; 1.0-8.0, P = 0.04) and a larger anteroposterior LA diameter (OR: 1.3; 95% CI; 1.1-1.6, P = 0.001) were independent predictors of AF recurrences at 6 months.
CONCLUSIONS: The recurrence rate in lone AF patients is high. The presence of previous episodes and a mildly enlarged anteroposterior LA diameter increase the probability of relapse of lone AF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998251     DOI: 10.1093/europace/eum233

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

Review 1.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

Review 2.  [Rate versus rhythm control with and without heart failure].

Authors:  Florian Straube; Uwe Dorwarth; Sabine Janko; Ellen Hoffmann
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

3.  Lone Atrial Fibrillation: Risk Factors, Triggers And Ablation Techniques.

Authors:  Mindy Vroomen; Laurent Pison
Journal:  J Atr Fibrillation       Date:  2015-06-30

4.  Assessing aeromedical risk: a three-dimensional risk matrix approach.

Authors:  Gary Gray; Dennis Bron; Eddie D Davenport; Joanna d'Arcy; Norbert Guettler; Olivier Manen; Thomas Syburra; Rienk Rienks; Edward D Nicol
Journal:  Heart       Date:  2019-01       Impact factor: 5.994

5.  Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study.

Authors:  Steven A Lubitz; Xiaoyan Yin; Michiel Rienstra; Renate B Schnabel; Allan J Walkey; Jared W Magnani; Faisal Rahman; David D McManus; Thomas M Tadros; Daniel Levy; Ramachandran S Vasan; Martin G Larson; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2015-03-13       Impact factor: 29.690

6.  Association of angiotensin-converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation.

Authors:  Xian-Ling Zhang; Li-Qun Wu; Xu Liu; Yi-Qing Yang; Hong-Wei Tan; Xin-Hua Wang; Li Zhou; Wei-Feng Jiang; Zheng Li
Journal:  Exp Ther Med       Date:  2012-07-31       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.